Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Source : https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext
Obesity is an epidemic and a public health threat. Medical weight management remains one of the options for the treatment of excess weight and recent advances have revolutionized how we...
Conclusions/Relevance: The choice of the anti-obesity medication needs to take into consideration the patient's clinical and biochemical profile, co-morbidities, and drug contra-indications, as well as expected degree of weight loss and improvements in cardio-renal and metabolic risk. It also remains to be seen whether precision medicine may...
Share
Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.975830/full
Objective: Based on the 4D label-free phosphoproteomic technique, we examined the differences in cognitive function and hippocampal phosphorylated protein expression in high-fat diet-induced obese mice after the intervention of semaglutide...
Conclusion: We found for the first time that a high-fat diet decreased CACNA1D, CACNA1A, and CACNA1B protein serine phosphorylation, which may affect neuronal development, synaptic plasticity, and cognitive function in mice. Notably, semaglutide and empagliflozin increased the phosphorylation of these proteins.
Share
Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC)
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2023.1136340/full
The prevalence of obesity worldwide has increased in recent decades not only among adults, but also in children and adolescents. This phenomenon contributes to an increased risk of cardiovascular diseases...
Relevance: The present executive paper is aimed to increase knowledge on the relationships between obesity and CVD, to raise the perception of this condition which is currently insufficient and to support the clinical practice management.
Share
Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36974746/
Health status in patients with HFpEF is impaired, especially in elderly, women, and those with obesity and comorbidities. Empagliflozin improved health status among all key subgroups studied with a greater...
Conclusion: Health status in patients with HFpEF is impaired, especially in elderly, women, and those with obesity and comorbidities. Empagliflozin improved health status among all key subgroups studied with a greater effect in obese patients.
Share
How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion
Source : https://www.internationaljournalofcardiology.com/article/S0167-5273(23)00465-5/fulltext
Obesity is an important independent cardiovascular (CV) risk factor and a chronic inflammatory disease related to the development of insulin resistance, type 2 diabetes, dyslipidaemia, coronary artery disease, hypertension, heart...
Conclusions/Relevance: The battle against the social and clinical stigma towards obesity must be counteracted by promoting an awareness that elevates obesity to a complex chronic disease. Several actions should be implemented to improve the management of obesity, and cardiologists have a key role for achieving a global approach to patients...
Share